osilodrostat + LCI699 matching placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Cushings Disease
Conditions
Cushings Disease
Trial Timeline
Oct 6, 2014 → Dec 4, 2019
NCT ID
NCT02180217About osilodrostat + LCI699 matching placebo
osilodrostat + LCI699 matching placebo is a phase 3 stage product being developed by Novartis for Cushings Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT02180217. Target conditions include Cushings Disease.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02180217 | Phase 3 | Completed |
Competing Products
3 competing products in Cushings Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Pasireotide with or without cabergoline | Novartis | Phase 2 | 52 |
| LCI699 | Novartis | Phase 2 | 52 |
| Pasireotide | Recordati | Pre-clinical | 20 |